Management of NSCLC with Common EGFR Mutations: Dr. Ben Levy
From Oncology Brothers: Practice-Changing Cancer Discussions · · 20 min
This plays from the publisher's own server. We do not host a copy.
Description
We dived into this evolving landscape of treatment options for common sensitizing EGFR mutations in non-small cell lung cancer (NSCLC). In this episode, we were joined by Dr. Benjamin Levy, a thoracic medical oncologist at Johns Hopkins, to discuss the latest advances in frontline therapies, including single-agent osimertinib, osimertinib plus chemotherapy, and the promising combination of amivantamab and lazertinib.
Key topics covered include:
- The prevalence of EGFR mutations in metastatic non-small cell adenocarcinoma
- The shift from single-agent osimertinib to combination therapies and the implications for patient care
- Factors influencing treatment decisions, including patient preference, side effect profiles, and co-mutations
- The importance of shared decision-making in oncology
- Insights into managing central nervous system (CNS) involvement and the nuances of treatment sequencing at progression
Whether you're a healthcare professional or simply interested in the latest in cancer treatment, this episode provides valuable insights into the complexities of managing EGFR-mutated lung cancer. Don't miss out on this informative discussion!
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966
Follow us on social media:
• X/Twitter: https://x.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Stay tuned for our next episode featuring Susan Scott, MD, where we will explore uncommon EGFR mutations.
#EGFRmNSCLC, #Osimertinib, #Amivantamab, #Lazertinib, #OncologyBrothers
Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem